The Life Sciences team advised City Therapeutics, Inc., on the completion of a $99.5 million Series B financing. Viking Global Investors and Sofinnova Investments participated in the financing as new investors, along with Casdin Capital and NYBC Ventures, joined by existing investors ARCH Venture Partners, Fidelity Management & Research Company, Invus, Slate Path Capital, Rock Springs Capital, Regeneron Ventures, AN Ventures, and other undisclosed investors. Proceeds will be used to advance City Therapeutics’ pipeline of RNAi therapeutics, accelerate the company’s next-generation RNAi engineering platform, and support business development activities.
City Therapeutics is a biopharmaceutical company harnessing its next-generation RNAi platform to improve and expand the reach of RNAi-based medicines. The company is building a pipeline of innovative RNAi therapeutics to make a significant impact for patients across multiple therapeutic areas. Co-founded by pioneering executives and scientists in RNAi, City Therapeutics is based in Cambridge, MA, and has raised over $230 million from leading life sciences investors.
The Goodwin team was led by Catherine Magazu, Libby Sousa, Bonnee Nie, and Kingsley Taft and included Lily Johnson Cardona, Robert Frederickson, Simone Waterbury, Ortal Ben Aharon, Gozde Guckaya, Kathryn Georgian, and Aniko Bouley.
For more information on the deal, please read the press release and see coverage from Fierce Biotech.